Check out your Company Bowl for anonymous work chats.
Looking for a partner at every stage of your journey? Our innovative research tools, automated analytical instruments, biomanufacturing and purification solutions are designed to make drug discovery and production simpler, faster, and more sustainable. But we don't just provide cutting-edge technology. We understand that our partners' development and production needs are unique - and we actively listen, anticipate and act to meet them. We're in this together. We offer leading solutions from drug discovery to production and final shipping. Discover our range of solutions at www.sartorius.com/inthistogether
Sartorius and SPARTA Biodiscovery, a spin-out company from Imperial College London, have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs. “The SPARTA platform will help customers optimize the design of nanoparticles at an early stage, even before the drug candidates move on to the clinic. We have teamed up to bring additional product commercialization and application expertise to the table to facilitate a swift transitioning from prototype to launch,” said Prof. Dr. Oscar-Werner Reif, Head of Corporate Research and CTO at Sartorius. Read press release: https://srtrs.info/dgpcj
Bringing personalized cell therapies to more people? Whether it is cancer, genetic disorders, or autoimmune diseases - there are high hopes for cell and gene therapies. Scientists and engineers explore new frontiers of drug discovery, development, and manufacturing to reveal the full potential of these advanced therapies and make them accessible to more patients. And we are right there with them. Because: We’re in this together. Let’s start working together at www.sartorius.com/inthistogether
This week, we celebrated a symbolic groundbreaking for the new production facility at our site in Freiburg, Germany. Let’s take this occasion to reflect on the beginnings of cytokine production at Sartorius CellGenix. Back in 2002, Fred Simon, a working student at that time, and some colleagues saw the chance to manufacture high-quality cytokines themselves when the available options didn’t meet GMP standards. Based on Fred's DNA, their idea led to the production of the first cytokines at CellGenix. Read on the Sartorius Blog, how Fred’s blood became a game changer, paving the way to becoming a leading player in pre-clinical and GMP cytokine production for the cell and gene therapy market, and how the team is growing with Sartorius: https://srtrs.info/gqtpu
Construction started in Freiburg! The symbolic groundbreaking today marked the start of a significant expansion of the existing production and R&D activities in Freiburg. In the Southwest of Germany, Sartorius is building a new center of excellence for developing and producing quality-critical materials for the cell and gene therapy market. With a gross floor area of almost 10,000 square meters, the new building will include production rooms, laboratories, and further space for technology and offices. The facility will be operated in a CO2-neutral manner, among other things, through the use of geothermal energy for heating, cold well water for cooling, photovoltaic power generation and a green facade. Read the press release for further details: srtrs.info/cellgenix-construction-en
MSCI, one of the world's leading providers of ESG ratings, upgraded Sartorius from A to AA in its recent analysis. This year, only 10% of companies received a higher rating. The scorecard consists of three categories: environmental, social and governance. Sartorius scored particularly well for "strong management practices to address carbon emissions relative to peers, including targets to reduce carbon emissions", "fewer apparent product recalls compared to peers", "governance practices that appear generally well aligned with investor interests", and "evidence of detailed policies on business ethics and corruption". Especially in the governance category MSCI rated Sartorius well above the industry average. Learn more about sustainability at Sartorius: www.sartorius.com/sustainability
MSCI, one of the world's leading providers of ESG ratings, upgraded Sartorius from A to AA in its recent analysis. This year, only 10% of companies received a higher rating. The scorecard consists of three categories: environmental, social and governance. Sartorius scored particularly well for "strong management practices to address carbon emissions relative to peers, including targets to reduce carbon emissions", "fewer apparent product recalls compared to peers", "governance practices that appear generally well aligned with investor interests", and "evidence of detailed policies on business ethics and corruption". Especially in the governance category MSCI rated Sartorius well above the industry average. Learn more about sustainability at Sartorius: www.sartorius.com/sustainability
How much startup is in your research? Around thirty PhD students and postdocs were invited to think about this question at a "phd-to-innovator" workshop at the Sartorius Campus in Göttingen. The two-day workshop, organized by Sartorius' partner Young Entrepreneurs in Science, aims to open up new career perspectives for highly qualified young researchers. The curriculum included personal reflection, training in entrepreneurial methods such as design thinking and a Q&A session with role models. Andrea Ernst, Head of Normal Flow Filtration Materials at Sartorius, participated as a mentor for intrapreneurship and shared her experiences: "In my journey from the lab to leading teams, I've found that innovation truly comes alive when research meets entrepreneurial spirit." Learn more about the event on the Sartorius blog: https://srtrs.info/phd-to-innovator-workshop
Working hard to bring personalized therapies to more people? Cell and gene therapies provide hope for patients in need of new medical solutions. These therapies have the potential to revolutionize treatments for genetic disorders, cancer, autoimmune diseases. To make these life-changing therapies accessible to more patients, our customers are pushing the boundaries of drug discovery, development, and manufacturing. And we are right at their side, committed to helping reveal the full potential of advanced therapies. We’re in this together. We enable faster and more affordable processes. Explore scalable solutions for more patients at www.sartorius.com/inthistogether
You’ll Never Research, Analyze, Develop, Optimize, or Work Alone Looking for a partner at every stage of your journey? With our innovative research tools, automated analytical instruments, bio-manufacturing and purification solutions, we aim to make drug discovery and production simpler, faster, and more sustainable. We don’t just understand the scientific aspects of our partners' research, development, and production. We listen, we act, we anticipate according to their very specific situations – from start to finish. We’re in this together. We offer leading solutions from drug discovery to production and final shipping. Discover our range of solutions at www.sartorius.com/inthistogether
